Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Moderna, Inc.

Moderna Inc is experiencing a decline, paralleling the broader market's downturn. Morgan Stanley has maintained an Equal-Weight rating on the compa...

Moderna faces decline amid FDA's black box warning review. Morgan Stanley cuts price target, while Jefferies initiates coverage with Hold rating.

Moderna, Inc. has announced a license and option agreement with Nanexa AB for the development of PharmaShell-based products. The agreement includes...

Moderna partners with Nanexa for PharmaShell products. $3M upfront, potential $500M in milestones boosts investor confidence.

Moderna Inc (MRNA) has experienced a price increase of 2.4% since Tuesday. Following market hours yesterday, it was reported that the FDA has begun...

Moderna's stock rises amid FDA investigation into vaccine links to adult fatalities. Increased Tires & Rubber sector performance suggests positive...

Moderna Inc (MRNA) is currently experiencing scrutiny as the FDA expands its investigation into COVID-19 vaccine safety to include adults. This com...

Moderna faces FDA scrutiny over adult COVID-19 vaccine safety. Public concern grows as links to fatalities are investigated, impacting market senti...

Moderna Inc's stock has increased significantly today, marking an overall rise since its low on November 21. The stock has experienced a notable re...

Moderna Inc's stock surges today, reflecting strong market interest. The recovery since November 21 highlights significant investor confidence.

Moderna's Chief Financial Officer recently purchased 568 shares of the company, a move interpreted as a sign of confidence in its future prospects....

Moderna CFO buys 568 shares, signaling confidence. He defends vaccine safety at Piper Sandler conference amid upcoming ACIP meeting concerns.

The FDA's top vaccine regulator outlines proposed changes to the vaccine evaluation process in an internal memo.

Moderna and Novavax Stocks Drop as FDA Proposes Stricter Vaccine Approvals

Moderna Inc. shares have dropped significantly, reflecting a broader sell-off among major COVID-19 vaccine manufacturers. This decline follows the...

Moderna shares plummet amid FDA's stricter vaccine standards. Concerns over potential links to pediatric deaths intensify market anxiety ahead of C...

Moderna Inc. has experienced a price target reduction to 63.00 per share from 69.00 by Piper Sandler, suggesting a potential upside of 152%. Conver...

Piper Sandler cuts Moderna's price target to $63. Social media buzz suggests monitoring MRNA for recovery above $26 amid correlated market trends.

Moderna Inc has seen its stock price increase following the recent report of the first confirmed human infection with the H5N5 strain of avian infl...

Moderna's stock rises as H5N5 avian flu case reported. Market anticipates increased vaccine demand amid ongoing health monitoring.

Moderna Inc is experiencing a price increase, coinciding with a significant upward movement in the Biotechnology sector. The company has recently a...

Moderna's stock rises amid biotech sector gains. Discontinuation of three mRNA programs fuels social media discussions.

Moderna Inc. is experiencing a price increase, aligning with the broader market's upward movement. The company announced a five-year credit facilit...

Moderna secures $1.5B credit facility, boosting investor confidence. The firm targets cash breakeven by 2028 and plans vaccine franchise expansion.

Moderna said on Thursday it secured a five-year loan of $1.5 billion from Ares Management , as it targets up to 10% revenue growth next year.

Moderna takes $1.5 billion loan, expects 10% revenue growth next year

Moderna said on Wednesday it would now operate full end-to-end manufacturing for its mRNA medicines in the U.S., marking a major step in strengthen...